[updated February 24, 1999]

 
 
 

Table 4. Death and Secondary Noncardiovascular Outcomes by Treatment Group*


 
             Treatment Group               

Outcomes
Estrogen-Progestin (n=1380)
Placebo
(n=1383)
RH (95% CI)
P Value
Death        
   CHD death
  70
  59
1.20 (0.85-1.69)
0.31
   Cancer death
  21
  24
0.88 (0.49-1.59)
0.68
   Non CHD/non-cancer death
  39
  40
0.98 (0.63-1.53)
0.94
   Unadjudicated death
    0
    0
    
   Total deaths
130
123
1.07 (0.83-1.37)
0.61
Venous thromboembolic event        
   Deep vein thrombosis
  25
    9
2.82 (1.31-6.03)
0.008
   Pulmonary embolism
  11
    4
2.79 (0.89-8.75)
0.08
   Any thromboembolic event
  34
  13
2.66 (1.40-5.04)
0.003
Cancer        
   Breast
  34
  25
1.38 (0.82-2.31)
0.22
   Endometrial
    2
    5
0.39 (0.08-2.00)
0.26
   Other
  66
  63
1.06 (0.75-1.49)
0.75
   Any cancer
101
  91
1.12 (0.85-1.49)
0.42
Fracture        
   Hip
   14
   13
1.09 (0.51-2.31)
0.83
   Other
127
138
0.93 (0.73-1.18)
0.55
   Any fracture
138
148
0.94 (0.75-1.19)
0.61
Gallbladder disease
  89
  67
1.34 (0.98-1.84)
0.07

* RH indicates relative hazard; CI, confidence interval; CHD, coronary heart disease.
Each row represents the number of women with the designated event; women with more than 1 type of event may appear
in more than 1 row.